Table 2 T1abc stage MpBC survival outcomes of patients following chemotherapy treatment or not.
Treatment | Overall survival | Breast cancer-specific survival | ||||
|---|---|---|---|---|---|---|
5-year survival (95 CI, %) | 10-year survival (95 CI, %) | 15-year survival (95 CI, %) | 5-year survival (95 CI, %) | 10-year survival (95 CI, %) | 15-year survival (95 CI, %) | |
T1a | ||||||
Chemotherapy | 62.500 (0.365–1.000) | 62.500 (0.365–1.000) | 62.500 (0.365–1.000) | 85.714 (0.633–1.000) | 85.714 (0.633–1.000) | 85.714 (0.633–1.000) |
Chemotherapy-naïve/Unknown | 80.000 (0.516–1.000) | 53.333 (0.214–1.000) | - | 100.000 (1.000–1.000) | 100.000 (1.000–1.000) | - |
T1b | ||||||
Chemotherapy | 100.000 (1.000–1.000) | 94.737 (0.852–1.000) | 94.737 (0.852–1.000) | 100.000 (1.000–1.000) | 100.000 (1.000–1.000) | 100.000 (1.000–1.000) |
Chemotherapy-naïve/Unknown | 92.888 (0.863–0.999) | 76.138 (0.627–0.924) | 45.683 (0.218–0.959) | 95.861 (0.904–1.000) | 91.503 (0.821–1.000) | 91.503 (0.821–1.000) |
T1c | ||||||
Chemotherapy | 91.347 (0.869–0.960) | 83.623 (0.770–0.909) | 81.300 (0.736–0.898) | 96.324 (0.935–0.993) | 93.000 (0.885–0.978) | 90.416 (0.839–0.974) |
Chemotherapy-naïve/Unknown | 79.842 (0.745–0.855) | 67.236 (0.602–0.751) | 53.046 (0.426–0.660) | 88.547 (0.842–0.931) | 83.992 (0.784–0.900) | 83.992 (0.784–0.900) |
